RESUMO
Adoptive immunotherapy using autologous Epstein-Barr virus (EBV)-specific cytotoxic T-lymphocytes (auto-CTL) can regress posttransplant lymphoproliferative disorders (PTLD). Widespread applicability of auto-CTL remains constrained. Generation is time-consuming, and auto-CTL cannot be established in patients treated with the B-cell depleting antibody rituximab. By contrast, pregenerated allogeneic CTL (allo-CTL) offers immediate accessibility. Allo-CTL has previously shown efficacy in "early" polyclonal- PTLD. We treated three patients with aggressive, advanced monoclonal-PTLD following solid-organ transplantation. All were refractory to at least three prior therapies. Despite HLA disparity, there was negligible toxicity, with early in vivo antiviral efficacy and reconstitution of EBV peptide-specific immunity. Two patients attained complete remission (CR). One remains in CR 17 months following therapy, coincident with persistence of donor-derived tumor targeted EBV-specific CTL; the other died of non-PTLD related pathology. In the third patient, autopsy demonstrated homing of allo-CTL at the tumor site. Larger prospective studies of EBV-specific allo-CTL in PTLD are warranted.
Assuntos
Transplante de Coração/efeitos adversos , Imunoterapia Adotiva/métodos , Transplante de Rim/efeitos adversos , Transplante de Pulmão/efeitos adversos , Transtornos Linfoproliferativos/imunologia , Transtornos Linfoproliferativos/terapia , Adolescente , Anticorpos Monoclonais/imunologia , Anticorpos Antivirais/imunologia , Feminino , Transplante de Coração/imunologia , Herpesvirus Humano 4/imunologia , Humanos , Transplante de Rim/imunologia , Transplante de Pulmão/imunologia , Pessoa de Meia-Idade , Receptores de Retorno de Linfócitos/imunologia , Linfócitos T Citotóxicos/imunologia , Linfócitos T Citotóxicos/patologia , Carga ViralRESUMO
Hyper-CVAD is a dose intensive chemotherapy regimen that has been used successfully in lymphoblastic lymphoma and leukaemia. However, the effect on ovarian function has not been evaluated. Thus, we undertook a retrospective analysis of patients under 40 years of age who had Hyper-CVAD as initial therapy and documented ovarian function as defined by regular menstruation off hormonal agents or naturally conceiving. Of the 12 patients identified, 7 were evaluable. Median age was 25. Six patients had resumption of regular menstruation and three of these women have conceived naturally. In conclusion, resumption of normal fertility is probable post-treatment with Hyper-CVAD.
Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Fertilidade/efeitos dos fármacos , Leucemia/tratamento farmacológico , Ovário/efeitos dos fármacos , Leucemia-Linfoma Linfoblástico de Células Precursoras/tratamento farmacológico , Adulto , Protocolos de Quimioterapia Combinada Antineoplásica/administração & dosagem , Ciclofosfamida/administração & dosagem , Dexametasona/administração & dosagem , Doxorrubicina/administração & dosagem , Feminino , Humanos , Leucemia/fisiopatologia , Ovário/fisiopatologia , Leucemia-Linfoma Linfoblástico de Células Precursoras/fisiopatologia , Vincristina/administração & dosagemRESUMO
Autologous stem cell transplantation (ASCT) for primary systemic amyloidosis (AL) produces high hematologic and organ responses. However, treatment-related mortality remains high and reported series are subject to selection bias. In all, 48 of 80 amyloid patients referred to our center had AL in the absence of myeloma, 26 of these 48 were deemed transplant candidates and 20 actually underwent ASCT. Transplant-related mortality has fallen from 50 to 20% since January 1999 due to better patient selection and prophylactic measures. Intent-to-treat organ responses were renal (46%), cardiac (25%) and liver (50%). Organ responses in patients who survived transplantation were renal (75%), cardiac (40%) and liver (100%). The 3-year OS post-ASCT was 56% with improved outcome predicted by a better performance status (P=0.08), normal ALP (P=0.08), nephrotic syndrome (P=0.01) and the absence of severe hypotension (P=0.01). The 3-year OS for all referred patients was 44% and this was not significantly better for transplant candidates. Patients with significant hypotension (systolic blood pressure < or =90 mmHg) or poor performance status (ECOG >2) have an exceedingly high treatment-related mortality and should not be transplanted. For those undergoing ASCT, organ response rates appear promising, but conclusive evidence of improved survival for this select group of patients is still lacking and will require randomized trials.